[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pulmonary-nodule-multiple\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pulmonary-nodule-multiple":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,42],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100469205","dolce-determining-the-impact-of-optellums-lung-cancer-prediction-solution-100469205",false,"NCT05389774","DOLCE: Determining the Impact of Optellum's Lung Cancer Prediction Solution","DOLCE: Determining the Impact of Optellum's Lung Cancer Prediction (LCP) Artificial Intelligence Solution on Service Utilisation, Health Economics and Patient Outcomes","DOLCE","Inclusion Criteria:\n\nPatients are eligible for the study if all of the following apply:\n\n* Are aged 35 years or above\n* Have baseline CT study with at least one incidentally detected solid or part-solid (must have a solid component \\>=80%) pulmonary nodule that:\n\n  * is not fully calcified\n  * Is 5-30mm inclusive in maximum axial diameter for the whole lesion measured using manual electronic callipers\n* Have baseline CT study that includes at least one series that meets all of the following (training for this will be provided):\n\n  * Is of a type that meets VNC instructions for use\n  * Comprises at least one full-inspiration breath-hold scans without a high degree of contrast media and does not exhibit quality issues (e.g., motion artefacts)\n\nExclusion Criteria:\n\nPatients will be excluded from the study if any of the following apply:\n\n* Have received a diagnosis for cancer in the last 5 years\n* Have thoracic implants that impact the image appearance of the nodule\n* Have more than five reported pulmonary nodules of any size or type excluding fully calcified nodules (this criterion is used as a proxy due to the risk of being an infection or metastasis)\n* Have one or more additional nodules where any of the following applies:\n\n  * Are already undergoing follow-up according to pulmonary nodule management standard care\n  * Pure ground glass opacity (GGO) of \\>=5mm in maximum axial diameter for the whole lesion measured using manual electronic callipers\n  * \\>30mm in maximum axial diameter for the whole lesion measured using manual electronic callipers","ALL","35 Years",{"count":20,"type":21},2000,"ESTIMATED","OBSERVATIONAL","This study is a multi-centre prospective observational cohort study recruiting patients with 5-30mm solid and part-solid pulmonary nodules that have been detected on CT chest scans performed as part of routine practice. The aim is to determine whether physician decision making with the AI-based LCP tool, generates clinical and health-economic benefits over the current standard of care of these patients.",[25,26,27,28],"AI (Artificial Intelligence)","Pulmonary Nodule, Solitary","Pulmonary Nodule, Multiple","Lung Cancer","RECRUITING","2025-04-04",{"date":32,"type":33},"2025-04-08","ACTUAL",{"date":35,"type":33},"2023-03-23",{"date":37,"type":21},"2025-08",{"name":39,"class":40},"Nottingham University Hospitals NHS Trust","OTHER",10,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":4},"100475924","comparative-study-on-the-efficacy-and-safety-of-microwave-ablation-and-lobectomy-in-the-treatment-of-ground-glass-nodules-located-in-the-pulmonary-hilar-region-100475924","NCT05477251","Comparative Study on the Efficacy and Safety of Microwave Ablation and Lobectomy in the Treatment of Ground Glass Nodules Located in the Pulmonary Hilar Region","Inclusion Criteria:\n\n1. The age ranged from 18 to 75 years old, male or female;\n2. GGO lesions in the hilar region were diagnosed by imaging examination (CT \u002F PET-CT). During the follow-up of 6-12 months, the lesions increased by more than 2mm, the solid components increased, or there were obvious solid components, or the GGOs were judged to be highly malignant by imaging.\n3. The size of GGO lesions was 8mm-3cm, and the number of nodules was ≤ 3.\n4. There was no lymph node metastasis, intrapulmonary metastasis or distant organ metastasis;\n5. After multidisciplinary evaluation, the patients were feasible for lobectomy and CT guided microwave treatment;\n6. No bleeding tendency, normal coagulation function or coagulation dysfunction can be corrected after treatment;\n7. Patients and \u002For family members agreed to join the clinical trial and signed informed consent.\n\nExclusion Criteria:\n\n1. The general condition of the patient is very poor, ECOG physical fitness score \\> 2, unable to tolerate lobectomy and MWA treatment, or has relevant contraindications;\n2. The lesions had received other treatments before; patients with regional lymph node metastasis or distant metastasis or with pleural fluid and ascites;\n3. Patients with poor compliance;\n4. Severe heart, lung, kidney, brain and other important organ diseases;\n5. The researcher believes that it is not suitable for inclusion","18 Years","75 Years",{"count":51,"type":21},100,"INTERVENTIONAL",[54],"NA","GGO is a characteristic focus of early lung cancer. Due to the abundant peripheral blood vessels and bronchial tissues around the GGO lesions located in pulmonary hilar, only lobectomy could be used for the surgical treat of hilar GGO lesions which will make the significantly decline of the pulmonary function after surgery and affect the quality of life to a great extent. Our previous study has reported a new blunt-tip MWA electrode (MTC-3CA-II3, Vison Medical Inc.) for the treatment of GGO lesions. The blunt-tip MWA electrode could improve the safety of GGO ablation, significantly reduce the occurrence of bleeding and hemoptysis, which made it possible to ablate GGO in the hilar region safely. In this study, the blunt-tip MWA electrode was used in the treatment of patients with hilar GGO lesions, and the efficacy and safety of microwave ablation and lobectomy in the treatment of ground glass nodules located in the pulmonary hilar region were evaluated and compared.",[27,26],"NOT_YET_RECRUITING","2022-08-09",{"date":60,"type":33},"2022-08-11",{"date":62,"type":21},"2022-10-01",{"date":64,"type":21},"2026-12-31",{"name":66,"class":40},"RenJi Hospital"]